Safety Data Exchange Agreements: Who Does What, and By When, When Two Companies Share a Product

When a product is licensed, co-marketed, distributed or manufactured under contract, safety information has to travel between companies without delay or loss. The safety data exchange agreement is the document that makes this happen, or fails to.

Why an SDEA is needed

The legal duty to report remains with the marketing authorisation holder, whatever the commercial arrangement. When a partner has contact with reporters, handles complaints or runs a programme, the holder depends on that partner for information. An SDEA turns that dependence into a defined, auditable process. Inspectors expect to see agreements for the partners who matter, and the pharmacovigilance system master file is expected to describe the arrangements in place.

What a good SDEA contains

  • Scope: the products, territories and activities covered, and the safety information in scope, including special situations such as pregnancy exposure, medication errors, misuse and lack of effect.
  • Responsibilities: who is the marketing authorisation holder for reporting purposes, who handles which regulatory submissions, and who performs literature searches.
  • Timelines: how quickly each party forwards a report to the other, measured in calendar days and reflecting the regulatory clock rather than treating it as an afterthought.
  • Format and channel: the agreed data, the method of transfer, and the contact points on each side.
  • Reconciliation: how and how often case data are compared between the two safety databases.
  • Aggregate and signal activities: who contributes to periodic reports, risk management plans and signal detection.
  • Safety communications and changes: notice of safety issues, label updates and inspections.
  • Audit, termination and transition: continued exchange during and after the end of the relationship.

Common failures

Typical problems are an agreement that is signed late, after the product has already been on the market; timelines that are inconsistent with the 15-day rule once handling time is allowed for; contacts that are out of date; and no process to check that the exchange is really working. Another is the agreement that deals only with serious cases, when the partner may well hold non-serious ones the holder must also report.

Keeping it alive

An SDEA is not a one-off. Reconciliation results, late-forwarded cases and changes in the partner’s organisation should feed back into it. A short register of agreements, with owners, review dates and status, helps to keep the system under control and is useful on the day of an inspection.

How PQRA helps

PQRA can draft or review SDEAs, build a register of safety agreements across your partners and distributors, and design reconciliation and monitoring procedures. For companies entering the Greek or wider EU market through licensing partners, we can help align the agreement with local requirements.

Contact PQRA to discuss your pharmacovigilance system, in Greece and across the EU.

CATEGORIES:

Uncategorized

Tags:

No responses yet

Leave a Reply

Your email address will not be published. Required fields are marked *